LEADING A RENAISSANCE

IN KIDNEY DISEASE

TREATMENT

Main-Banner-v3B-01.jpg

 

FOCUS

 

Banners-05.png

Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.

Chronic kidney disease is a driver of mortality across age, race, and stage of disease progression, affecting over 1 in 9 people worldwide. It has emerged as a global epidemic and growing problem that places an enormous social and economic burden on patients, their families, and society.

Advances in kidney transplantation and dialysis over half a century ago extended life for patients with kidney failure, yet the current standard of care for patients with kidney disease remains inadequate, and there is an urgent need for new treatment options.

Recent breakthroughs in genetics and biology have generated an unparalleled understanding of the biological pathways that drive kidney disease. Goldfinch is uniquely positioned to translate these discoveries into new therapies that target the molecular causes of kidney disease.

 

The burden of kidney disease for patients and society

 

TEAM

 

Banners-07.png

Goldfinch brings together experts in the field and experienced leaders with a shared mission to pioneer new treatments for patients with kidney disease.

LEADERSHIP

Anthony Johnson, M.D.

Chief Executive Officer

Michael Broxson

Chief Business and Operating Officer

Jean-Christophe Harmange, Ph.D.

Senior Vice President of Drug Discovery

Peter Mundel, M.D.

Senior Vice President of Biology

Maria Beconi, Ph.D.

Vice President of Pharmacology and Non Clinical Development

Curtis Demick

Vice President of Human Resources

Thomas Tibbitts, Ph.D.

Vice President of Computational Discovery

Liron Walsh, M.D.

Vice President of Translational and Clinical Nephrology

Thomas Martz

Director of Corporate Development

FOUNDERS AND ADVISORS

Our Founders and Advisors are world-renowned scientists and clinicians at the forefront of kidney biology, genetics, and genomics.

Joseph Bonventre, M.D., Ph.D.

Harvard Medical School, MIT, Brigham and Women's Hospital

Anna Greka, M.D., Ph.D.

The Broad Institute, Harvard Medical School, Brigham and Women’s Hospital

Friedhelm Hildebrandt, M.D.

Harvard Medical School, Boston Children's Hospital

Daniel MacArthur, Ph.D.

The Broad Institute, Harvard Medical School, Massachusetts General Hospital

Peter Mundel, M.D.

Goldfinch Bio

Stefan Somlo, M.D.

Yale School of Medicine

BOARD OF DIRECTORS

Abbie Celniker, Ph.D.

Chairwoman of Goldfinch Bio and Partner, Third Rock Ventures

Louis Brenner, M.D.

President and Chief Operating Officer, Allena Pharmaceuticals

Neil Exter

Partner, Third Rock Ventures

Anthony Johnson, M.D.

Chief Executive Officer

 

APPROACH

 

Banners-06.png

Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease.

 
 

Goldfinch’s Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets for kidney disease.

 

PROGRAMS

 

Banners-08.png

Goldfinch’s therapeutic programs are underscored by strong genetic validation and a deep familiarity of the biological pathways that cause disease. Our initial efforts are focused on focal segmental glomerulosclerosis (FSGS) and polycystic kidney disease (PKD).


FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Programs-02-v2-01.png

Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder, is a histopathologic diagnosis characterized by severe scarring of the kidney's filtering units, or glomeruli, leading to an excess of essential proteins spilling into the urine, called proteinuria. FSGS is a leading cause of kidney failure, and patients with diagnosed FSGS are at increased risk of heart attack, stroke and premature death.

There are currently no FDA approved treatments for FSGS. Existing treatments are non-specific, do not alter the progression of disease and carry significant toxicities.

Goldfinch is leading the charge to develop treatments targeting the molecular causes of FSGS to drastically improve the lives of patients suffering from this devastating, life-shortening condition.


POLYCYSTIC KIDNEY DISEASE (PKD)

Programs-02-v2-01.png

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common single gene diseases, affecting more than 600,000 people in the US and 12 million worldwide. The disease is passed on from parent to child, with each child of an affected parent having a 1-in-2 chance of inheriting the disorder, which does not skip generations.

ADPKD patients develop fluid filled cysts in both kidneys that increase in number and size over time, culminating in end stage kidney disease in half of affected individuals by middle age. ADPKD commonly causes liver cysts which arise from bile ducts and can sometimes grow large enough to cause symptoms as well. In the United States, 1 in 20 individuals either on dialysis or with a kidney transplant has ADPKD.

There are no FDA approved therapies specifically targeting ADPKD and no means by which to alter the course of the disease.

Goldfinch is leveraging scientific discoveries based on the known genes that cause ADPKD to discover treatments to alter the course of ADPKD and drastically improve the lives of patients suffering from this chronic and debilitating disease.

 

Patients

 

Banners-05.png

It is the patients with kidney disease who will lead us to the understanding of pathways and targets that will drive transformative drug development. To accomplish this, we will partner with patients to build the world’s most comprehensive registry of individuals with molecularly defined kidney disease.

Goldfinch is assembling a database of genetic, genomic and clinical information from consented patients who have provided thousands of DNA samples and anonymized clinical records. Building off of the studies of our founders and partners, we will deeply study DNA and correlate findings with clinical data. We will then use novel computational tools to mine for evidence of the DNA variants that increase risk for kidney disease and suggest new ways to treat and prevent it.

 

CAREERS

 

Banners-06.png

At Goldfinch, we are pioneering a new approach to discover and develop therapeutics for kidney disease that is unprecedented.

Where others see risk, we see opportunity to make an impact and redefine the state of care for patients with kidney disease. We recognize the importance of collaboration, and strive to work alongside patients, clinicians and other partners to empower patients and develop treatments for conditions where no approved therapies exist.

We’re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.

If this sounds like the community you want to grow with, we invite you to explore our current career opportunities below.

If you would like to be considered for an opportunity at Goldfinch Bio, please submit your CV with the title of the position in the subject line to careers@goldfinchbio.com.

JOIN THE RENAISSANCE

Senior Research Associate, Biology

The Opportunity

The Senior Research Associate will develop, implement and execute in vivo and in vitro assays required for the advancement of high priority projects and Goldfinch Bio's Product Engine.

Major Responsibilities

  • Development and implementation of a diverse set of cellular assays used to support lead discovery
  • In partnership with scientific leadership design, execute, troubleshoot, and interpret biological experiments in support of program objectives
  • Interact and communicate results and conclusions to the biology team and cross-functional project teams

Requirements and Qualifications

  • B.S. or M.S. in cell and/or molecular biology or pharmacology
  • 3 to 5 years of industry experience
  • Experience developing cellular assays used to drive early-stage programs towards candidate selection, including miniaturization and automation of high-content imaging, as well as protein and RNA assays
  • Target validation experience with ability to assay target biology with genetic perturbation techniques such as CRISPR-Cas9 and shRNA, in addition to the construction of stable cell lines expressing genes of interest
  • Demonstrated ability to thrive in a team environment
  • Strong experimental background and a rigorous, analytical approach to problem solving
  • Familiarity with high-content phenotypic screening
  • Experience with visualization software and associated analysis of rich cellular datasets
  • Some weekend work will be required

Associate Director of Clinical Operations

The Role

The Director of Clinical Operations and Development will play a key role to manage, plan, and execute clinical development programs and studies, including creating and managing study timelines, budgets, and study management plans. Additionally, s/he will provide guidance and shared learning with and across teams throughout planning and implementation, as well as ensure clinical operational and development deliverables and timelines are met across the development program(s). This position will report to the Vice President, Clinical & Translational Nephrology.

Major Responsibilities

  • Responsible for the infrastructure build and creation of process for early-stage clinical development
  • Lead the evaluation, selection and management of Contract Research Organizations (CROs) and other external vendors to ensure successful clinical trial implementation and execution
  • Create, manage, and execute clinical operations and development programs, including study management, budget and timeline creation
  • Manage and lead CRO’s
  • Ability to build strong KOL, Principal Investigator relationships, and CRA’s with the ability to easily understand and explain complex scientific topics
  • Lead program development teams, and understand the intricacies among the different cross-functional groups, including medical affairs, HEOR, and other late-stage teams
  • Participate with clinical site staff and Investigators as appropriate to ensure optimal Sponsor-site relationships
  • Develop and ensure execution of activities outlined in various study plans (data management, safety management, and study communication plans)
  • Participate in preparation of regulatory filings (e.g. IND, pre-IND, orphan applications etc.) as needed
  • Partner with CMC/clinical supplies to provide drug supply assumptions and contribute to design and packaging of supplies for clinical trials
  • Manage all aspects of study progress from planning to close-out to assure adherence to intended timelines and achievement of study goals while ensuring quality in accordance with FDA, EMEA, GCP, and ICH guidelines
  • As appropriate, Lead, plan, and execute clinical Investigator meetings, study meetings, and vendor meetings as needed
  • Attend scientific conferences as needed

Requirements and Qualifications

  • Master’s Degree Preferred
  • 5 years of Clinical Operations experience within a sponsor company
  • Experience in All phases of development: HV, Phase 1-3, adaptive designs
  • Experience running programs in EU and the US
  • Must have rare disease experience and conducted First in Human Studies
  • Nephrology Therapeutic Area experience strongly preferred
  • Robust understanding and experience leading early-stage clinical development programs, including proof-of-concept, Phase 1, Phase 2, and through later development.
  • Must thrive working in a fast-paced, innovative environment while remaining flexible, proactive, resourceful and efficient
  • Demonstrated ability to translate strategy into action; excellent analytical skills and an ability to communicate complex issues in a simple way and to orchestrate plans to resolve issues and mitigate risks.
  • Understanding of drug development and program management from pre-IND through NDA
  • Extensive experience managing late-stage clinical programs, CROs, budgets, and timelines
  • Strong working knowledge of MS Project and developing Gantt charts
  • Experience monitoring clinical studies and conducting PSVs, SIVs, IMVs, and COVs required.
  • Management of CROs, multiple vendors, and complex protocols
  • A detailed understanding of overall strategic direction, interrelationships and business needs.
  • Proven experience in the oversight of the operational aspects of all stages of clinical studies

Principal Scientist, Biomarker and Translational Research

The Role

We’re seeking a highly motivated Principal Scientist with a strong background in disease characterization and biomarker technology to join our Pharmacology and Translational Science Department to contribute to building our pipeline for renal diseases. The successful candidate will focus on the discovery and progression of novel biomarkers and therapeutics for Goldfinch programs. Responsibilities include leading scientific research to identify, evaluate, and characterize relevant blood, urine, and kidney biomarkers that will provide useful pharmacodynamic and efficacy endpoints in preclinical and clinical settings.

Major Responsibilities

  • Develop strategy and scientific approach to identify novel diagnostic, prognostic, and pharmacodynamic biomarkers to enable scientific driven go/no go decisions for programs to assist in program progression.
  • Develop in vitro and biochemical assays to evaluate efficacy, PK/PD relationship, and novel biomarkers to characterize molecules for potential therapeutic effects.
  • Lead the identification and validation of novel biomarkers to enable scientific driven go/no go decisions for programs to assist in program progression.
  • Establish and manage external research collaborations to identify diagnostic and prognostic biomarkers for indications of interest in chronic kidney disease.
  • Participate in and lead cross-functional teams to support preclinical drug discovery and development.
  • Prepare, review and deliver high quality scientific presentations for internal/external use.
  • Commitment to help the team achieve deliverables and meet aggressive timelines.

Requirements and Qualifications

  • PhD with at least 6 years post-degree research in an industry setting.
  • Extensive hands-on experience with biomarker technology platforms, including untargeted and targeted mass spectrometry, ELISA, etc.
  • Hands-on experience in cellular and biochemical science such as standard molecular biology and protein biochemistry techniques.
  • Hands on experience in the development and validation of biomarker assays in the preclinical and clinical setting required.
  • Strong publication record and demonstrated experience conducting independent research, preferably in the field of monogenic diseases
  • Strong leadership and evidence of strategic scientific thinking.
  • Effective managerial skills and the ability to lead independent scientists with different skill sets.
  • Expertise in cutting edge assay technologies and proven assay troubleshooting skills.

Note to Recruitment Agencies: Please do not forward any agency resumes. Goldfinch Bio is not responsible for any fees related to resumes that are unsolicited.
 
Equal Opportunity Employer M/F/D/V.